A Surge of DNA Damage Links Transcriptional Reprogramming and Hematopoietic Deficit in Fanconi Anemia.


Journal

Molecular cell
ISSN: 1097-4164
Titre abrégé: Mol Cell
Pays: United States
ID NLM: 9802571

Informations de publication

Date de publication:
17 12 2020
Historique:
received: 30 07 2019
revised: 26 07 2020
accepted: 23 11 2020
entrez: 18 12 2020
pubmed: 19 12 2020
medline: 16 1 2021
Statut: ppublish

Résumé

Impaired DNA crosslink repair leads to Fanconi anemia (FA), characterized by a unique manifestation of bone marrow failure and pancytopenia among diseases caused by DNA damage response defects. As a germline disorder, why the hematopoietic hierarchy is specifically affected is not fully understood. We find that reprogramming transcription during hematopoietic differentiation results in an overload of genotoxic stress, which causes aborted differentiation and depletion of FA mutant progenitor cells. DNA damage onset most likely arises from formaldehyde, an obligate by-product of oxidative protein demethylation during transcription regulation. Our results demonstrate that rapid and extensive transcription reprogramming associated with hematopoietic differentiation poses a major threat to genome stability and cell viability in the absence of the FA pathway. The connection between differentiation and DNA damage accumulation reveals a novel mechanism of genome scarring and is critical to exploring therapies to counteract the aplastic anemia for the treatment of FA patients.

Identifiants

pubmed: 33338401
pii: S1097-2765(20)30840-6
doi: 10.1016/j.molcel.2020.11.040
pmc: PMC8600940
mid: NIHMS1653390
pii:
doi:

Substances chimiques

Formaldehyde 1HG84L3525

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1013-1024.e6

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES028096
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA190635
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA157448
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA204020
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA193124
Pays : United States
Organisme : NIEHS NIH HHS
ID : P42 ES004705
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM066698
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests The authors declare no conflict of interests.

Références

Nat Rev Mol Cell Biol. 2016 Jun;17(6):337-49
pubmed: 27145721
Mol Cell. 2014 Jun 5;54(5):858-69
pubmed: 24905007
Nature. 2006 Feb 16;439(7078):811-6
pubmed: 16362057
Curr Stem Cell Res Ther. 2008 Dec;3(4):237-46
pubmed: 19075754
Nat Rev Mol Cell Biol. 2015 Aug;16(8):455-60
pubmed: 26130008
Cell Cycle. 2014;13(10):1540-50
pubmed: 24626199
Nat Genet. 2003 Oct;35(2):165-70
pubmed: 12973351
Mutat Res. 1996 Jul 10;369(1-2):13-21
pubmed: 8700178
Cell Syst. 2017 Apr 26;4(4):416-429.e3
pubmed: 28365152
Nat Commun. 2018 May 15;9(1):1898
pubmed: 29765026
Science. 2013 Feb 15;339(6121):823-6
pubmed: 23287722
Cell Cycle. 2012 Nov 1;11(21):3983-96
pubmed: 22987153
Mol Cell. 2010 Feb 26;37(4):492-502
pubmed: 20188668
Mol Cell. 2005 Oct 28;20(2):187-98
pubmed: 16246722
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63
pubmed: 17548814
Mol Cell. 2009 Sep 11;35(5):716-23
pubmed: 19748364
Nature. 2009 Jul 2;460(7251):53-9
pubmed: 19483674
Mol Cell. 2019 Feb 7;73(3):574-588.e7
pubmed: 30595436
Cell. 2014 Oct 23;159(3):558-71
pubmed: 25417107
Curr Opin Cell Biol. 2015 Dec;37:49-60
pubmed: 26512453
Stem Cells. 2004;22(7):1142-51
pubmed: 15579635
Cell. 2004 Dec 29;119(7):941-53
pubmed: 15620353
Cell Res. 2008 Jan;18(1):73-84
pubmed: 18166977
Nature. 2011 Jul 06;475(7354):53-8
pubmed: 21734703
Mol Cell. 2001 Feb;7(2):249-62
pubmed: 11239454
Nat Rev Cancer. 2018 Mar;18(3):168-185
pubmed: 29376519
Toxicol Sci. 2015 Jul;146(1):170-82
pubmed: 25904104
Nat Rev Mol Cell Biol. 2012 Apr 04;13(5):297-311
pubmed: 22473470
Nat Struct Mol Biol. 2011 Nov 13;18(12):1432-4
pubmed: 22081012
N Engl J Med. 2010 May 20;362(20):1909-19
pubmed: 20484397
Mol Cell. 2015 Nov 5;60(3):351-61
pubmed: 26593718
Cancer Cell. 2012 Jul 10;22(1):106-16
pubmed: 22789542
Carcinogenesis. 1992 Aug;13(8):1485-9
pubmed: 1499101
Immunol Rev. 2004 Aug;200:115-31
pubmed: 15242400
Cell Rep. 2020 Jan 28;30(4):1235-1245.e4
pubmed: 31995761
Cell Rep. 2014 Jun 26;7(6):1849-57
pubmed: 24910428
Nature. 2018 Jan 11;553(7687):171-177
pubmed: 29323295
Mol Cell Proteomics. 2017 Apr;16(4):581-593
pubmed: 28153913
Cell. 2014 Oct 9;159(2):346-57
pubmed: 25303529
Chem Res Toxicol. 2012 Mar 19;25(3):664-75
pubmed: 22148432
Chem Sci. 2017 May 1;8(5):4073-4081
pubmed: 28580121
Cell. 2007 Sep 21;130(6):991-1004
pubmed: 17889645
Blood. 2006 Mar 1;107(5):2162-9
pubmed: 16269619
Cell. 2007 Apr 20;129(2):289-301
pubmed: 17412408
J Biol Chem. 2017 Dec 8;292(49):20184-20195
pubmed: 29021208

Auteurs

Xi Shen (X)

Department of Experimental Radiation Oncology, the University of Texas, MD Anderson Cancer, Houston, TX 77030, USA.

Rui Wang (R)

Department of Experimental Radiation Oncology, the University of Texas, MD Anderson Cancer, Houston, TX 77030, USA.

Moon Jong Kim (MJ)

Department of Experimental Radiation Oncology, the University of Texas, MD Anderson Cancer, Houston, TX 77030, USA.

Qianghua Hu (Q)

Department of Experimental Radiation Oncology, the University of Texas, MD Anderson Cancer, Houston, TX 77030, USA.

Chih-Chao Hsu (CC)

Department of Epigenetics and Molecular Carcinogenesis, the University of Texas, MD Anderson Cancer, Houston, TX 77030, USA.

Jun Yao (J)

Department of Molecular Oncology, the University of Texas, MD Anderson Cancer, Houston, TX 77030, USA.

Naeh Klages-Mundt (N)

Department of Experimental Radiation Oncology, the University of Texas, MD Anderson Cancer, Houston, TX 77030, USA.

Yanyan Tian (Y)

Department of Experimental Radiation Oncology, the University of Texas, MD Anderson Cancer, Houston, TX 77030, USA.

Erica Lynn (E)

Department of Experimental Radiation Oncology, the University of Texas, MD Anderson Cancer, Houston, TX 77030, USA.

Thomas F Brewer (TF)

Department of Chemistry, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.

Yilei Zhang (Y)

Department of Experimental Radiation Oncology, the University of Texas, MD Anderson Cancer, Houston, TX 77030, USA.

Banu Arun (B)

Department of Breast Medical Oncology, the University of Texas, MD Anderson Cancer, Houston, TX 77030, USA.

Boyi Gan (B)

Department of Experimental Radiation Oncology, the University of Texas, MD Anderson Cancer, Houston, TX 77030, USA.

Michael Andreeff (M)

Department of Leukemia, the University of Texas, MD Anderson Cancer, Houston, TX 77030, USA.

Shunichi Takeda (S)

Department of Radiation Biology, Kyoto University, 606-8501 Kyoto, Japan.

Junjie Chen (J)

Department of Experimental Radiation Oncology, the University of Texas, MD Anderson Cancer, Houston, TX 77030, USA.

Jae-Il Park (JI)

Department of Experimental Radiation Oncology, the University of Texas, MD Anderson Cancer, Houston, TX 77030, USA.

Xiaobing Shi (X)

Department of Epigenetics and Molecular Carcinogenesis, the University of Texas, MD Anderson Cancer, Houston, TX 77030, USA.

Christopher J Chang (CJ)

Department of Chemistry, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.

Sung Yun Jung (SY)

Department of Biochemistry, Baylor College of Medicine, Houston, TX 77030, USA.

Jun Qin (J)

Department of Biochemistry, Baylor College of Medicine, Houston, TX 77030, USA.

Lei Li (L)

Department of Experimental Radiation Oncology, the University of Texas, MD Anderson Cancer, Houston, TX 77030, USA; Life Sciences Institute, Zhejiang University, Hangzhou 310058, China. Electronic address: leili852002@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH